+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Colorectal Cancer Drugs Market by Drug Class, Distribution Channel, Route Of Administration, Line Of Therapy, Target Molecule, Treatment Setting - Global Forecast to 2030- Product Image
Colorectal Cancer Drugs Market by Drug Class, Distribution Channel, Route Of Administration, Line Of Therapy, Target Molecule, Treatment Setting - Global Forecast to 2030- Product Image
Sale

Colorectal Cancer Drugs Market by Drug Class, Distribution Channel, Route Of Administration, Line Of Therapy, Target Molecule, Treatment Setting - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4896776
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The colorectal cancer drugs market is undergoing rapid transformation as new therapies, advanced diagnostics, and evolving regulatory frameworks shape the external and internal landscape for industry stakeholders. Senior decision-makers must act on critical industry shifts to maintain a competitive edge and drive patient benefit.

Market Snapshot: Colorectal Cancer Drugs Market Growth

The Colorectal Cancer Drugs Market grew from USD 11.36 billion in 2024 to USD 11.95 billion in 2025. It is expected to continue growing at a CAGR of 5.16%, reaching USD 15.37 billion by 2030. This expansion results from breakthrough therapeutics and a dynamic global demand for improved patient outcomes. Momentum is driven by novel immunotherapies, refined chemotherapy agents, and the integration of biomarker-driven strategies within standard care protocols. Leading regions demonstrate innovation and access across public and private healthcare sectors, while suppliers, manufacturers, and pharmaceutical companies navigate an increasingly complex distribution ecosystem.

Scope & Segmentation

This comprehensive research report analyzes the Colorectal Cancer Drugs Market through a multilayered segmentation, highlighting opportunities for product innovation, regional penetration, and precise patient targeting.

  • Drug Class: Chemotherapy (fluoropyrimidines, platinum compounds, topoisomerase inhibitors), immunotherapy (adoptive cell therapies, checkpoint inhibitors), monoclonal antibodies (epidermal growth factor receptor inhibitors, vascular endothelial growth factor inhibitors), small molecule inhibitors (BRAF, MEK, tyrosine kinase inhibitors).
  • Distribution Channel: Hospital pharmacies, online pharmacies, retail pharmacies.
  • Route of Administration: Intravenous, oral, subcutaneous.
  • Line of Therapy: First line, second line, third line.
  • Target Molecule: Epidermal growth factor receptor, programmed cell death protein 1, programmed death ligand 1, vascular endothelial growth factor.
  • Treatment Setting: Inpatient, outpatient.
  • Region: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, and others), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Leading Companies: F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, Amgen Inc., Bayer AG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Laboratoires Servier SAS, Taiho Pharmaceutical Co., Ltd.

Key Takeaways

  • Innovations in immunotherapy and molecular targeting are reshaping therapy design, with a focus on improved patient survival and tolerability.
  • Personalized medicine is advancing, as biomarker-driven approaches and precision medicine become essential in therapy selection and clinical trial enrollment.
  • Regional market variations require differentiated strategies, as payer dynamics, reimbursement policies, and healthcare infrastructure vary substantially across global markets.
  • Distribution channels are diversifying, driven by the expansion of online pharmacies and demand for oral and subcutaneous formulations that support outpatient care and increase convenience.
  • Collaboration between big pharma, biotech firms, and diagnostics developers is fueling pipeline growth, accelerating the introduction of novel compounds and combination regimens.
  • Strategic adaptation to evolving administration routes and line-of-therapy requirements enables companies to effectively serve both treatment-naïve and refractory patient populations.

Tariff Impact

Adjustment of U.S. tariffs on key active pharmaceutical ingredients and biologic components starting in 2025 will impact import costs for colorectal cancer drug manufacturers. Companies sourcing monoclonal antibody precursors or certain small molecule intermediates internationally may need to reassess supply-chain and contract manufacturing arrangements. This may particularly affect smaller biotechnology firms, prompting a review of supplier relationships and encouraging vertical integration or investment in domestic production capabilities. Strategic alliances and heightened supply chain agility are expected to play a greater role in mitigating these shifts.

Methodology & Data Sources

The analysis combines primary research, including in-depth interviews with oncology professionals and industry stakeholders, with secondary research based on peer-reviewed publications, regulatory updates, and industry reports. Market segmentation was validated by qualitative and quantitative assessment, cross-sectional analysis, and scenario evaluation of regulatory and tariff influences.

Why This Report Matters

  • Enables senior leaders to anticipate disruptive market, regulatory, and technology trends before they impact operations.
  • Delivers actionable insights for optimizing R&D, commercialization, and supply chain decisions across multiple regional markets.
  • Supports data-driven strategic planning for partnerships, risk management, and portfolio prioritization in the colorectal cancer drugs market.

Conclusion

This report distills complex market forces and advanced scientific developments into clear strategic guidance for stakeholders navigating the global colorectal cancer drugs sector. Leveraging these insights supports informed, agile decision-making and sustained growth as innovation continues to reshape the oncology landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Colorectal Cancer Drugs Market, by Drug Class
8.1. Introduction
8.2. Chemotherapy
8.2.1. Fluoropyrimidines
8.2.2. Platinum Compounds
8.2.3. Topoisomerase Inhibitors
8.3. Immunotherapy
8.3.1. Adoptive Cell Therapies
8.3.2. Checkpoint Inhibitors
8.4. Monoclonal Antibodies
8.4.1. Epidermal Growth Factor Receptor Inhibitors
8.4.2. Vascular Endothelial Growth Factor Inhibitors
8.5. Small Molecule Inhibitors
8.5.1. BRAF Inhibitors
8.5.2. MEK Inhibitors
8.5.3. Tyrosine Kinase Inhibitors
9. Colorectal Cancer Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Colorectal Cancer Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
11. Colorectal Cancer Drugs Market, by Line Of Therapy
11.1. Introduction
11.2. First Line
11.3. Second Line
11.4. Third Line
12. Colorectal Cancer Drugs Market, by Target Molecule
12.1. Introduction
12.2. Epidermal Growth Factor Receptor
12.3. Programmed Cell Death Protein 1
12.4. Programmed Death Ligand 1
12.5. Vascular Endothelial Growth Factor
13. Colorectal Cancer Drugs Market, by Treatment Setting
13.1. Introduction
13.2. Inpatient
13.3. Outpatient
14. Americas Colorectal Cancer Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Colorectal Cancer Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Colorectal Cancer Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. F. Hoffmann-La Roche Ltd.
17.3.2. Merck & Co., Inc.
17.3.3. Bristol-Myers Squibb Company
17.3.4. Amgen Inc.
17.3.5. Bayer AG
17.3.6. Pfizer Inc.
17.3.7. Eli Lilly and Company
17.3.8. AstraZeneca plc
17.3.9. Laboratoires Servier SAS
17.3.10. Taiho Pharmaceutical Co., Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. COLORECTAL CANCER DRUGS MARKET MULTI-CURRENCY
FIGURE 2. COLORECTAL CANCER DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. COLORECTAL CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2030 (%)
FIGURE 18. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. COLORECTAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. COLORECTAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. COLORECTAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED DEATH LIGAND 1, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 67. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 69. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 70. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 71. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 72. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 75. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 76. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 77. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 79. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 80. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 81. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 85. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 86. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 128. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 130. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 131. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 132. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 133. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 136. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 137. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 138. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 140. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 141. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 142. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 146. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 147. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 158. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 160. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 161. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 162. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 163. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 166. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 167. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 168. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 170. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 171. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 172. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 173. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 176. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 177. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 208. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 210. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 211. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 212. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 213. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 216. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 217. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 228. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 229. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 230. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 231. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 232. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 233. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 236. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 237. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 238. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 240. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 241. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 242. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 243. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 246. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 247. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 268. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 270. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 271. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 272. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 273. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 276. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 277. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 278. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 279. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 280. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 281. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 282. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 283. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 286. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 287. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 288. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 298. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 299. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 300. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 301. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 302. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 303. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 304. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 305. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 306. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2030 (USD MILLION)
TABLE 307. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 308. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 309. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 310. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 311. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 312. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 313. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 314. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 316. POLAND COLORECT

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Colorectal Cancer Drugs market report include:
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Bayer AG
  • Pfizer Inc.
  • Eli Lilly and Company
  • AstraZeneca plc
  • Laboratoires Servier SAS
  • Taiho Pharmaceutical Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.95 Billion
Forecasted Market Value ( USD ) by 2030 $ 15.37 Billion
Compound Annual Growth Rate5.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Metastatic Colorectal Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Metastatic Colorectal Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Colorectal Cancer Drugs Market Report 2025 - Product Image

Colorectal Cancer Drugs Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Metastatic Colorectal Cancer - Pipeline Insight, 2025 - Product Image

Metastatic Colorectal Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • 280 Pages
  • Global
From
Colorectal Cancer - Pipeline Insight, 2025 - Product Image

Colorectal Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • 550 Pages
  • Global
From
Colorectal Cancer (CRC) Pipeline Analysis Report - Product Image

Colorectal Cancer (CRC) Pipeline Analysis Report

  • Report
  • 150 Pages
  • Global
From

About the Colorectal Cancer Drug Market

The Colorectal Cancer Drug market is composed of drugs used to treat colon cancer. These drugs are used to reduce the size of tumors, reduce the spread of cancer cells, and reduce the risk of recurrence. Commonly used drugs include chemotherapy, targeted therapy, immunotherapy, and hormone therapy. Chemotherapy is the most common treatment for colon cancer, and is used to kill cancer cells. Targeted therapy is used to target specific molecules in cancer cells, while immunotherapy is used to boost the body’s immune system to fight cancer. Hormone therapy is used to reduce the production of hormones that can cause cancer cells to grow. Companies in the Colorectal Cancer Drug market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.